Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CDSCO rejects GSK...

    CDSCO rejects GSK request to skip Phase III trial for Influenza Vaccine for higher age groups

    Meghna A SinghaniaBy Meghna A SinghaniaPublished On 2019-05-22T17:25:50+05:30  |  Updated On 2021-08-17T13:04:56+05:30

    New Delhi: One of the oldest pharmaceutical and healthcare companies in India, GlaxoSmithKline recently presented before the Subject Expert Committee functional under the Central Drugs Standard Control Organization (CDSCO) for a waiver of clinical trial of Inactivated Influenza Vaccine (Split Virion). However, CDSCO did not grant permission to skip the clinical trial and directed them to conduct the Phase III trial.


    The recommendation came after the firm presented the proposal for waiver of the clinical trial requirement for an extension of the indication to higher age groups.


    Much to its dismay, the committee did not rule in favour of the proposal presented by GSK. Instead, the SEC committee recommended that "the firm should conduct Phase III local clinical trial in the proposed age group."


    An inactivated vaccine (or killed vaccine) is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed, thereby implying extra caution needs to be exercised as compared to a drug (formulation) trial.


    According to the WHO guidelines for clinical evaluation of vaccines, the phase III studies that are large-scale clinical trials designed to provide data on vaccine efficacy and safety are necessary.


    These studies are usually performed in large populations to evaluate the efficacy and safety of formulation(s) of the immunologically active component(s).


    A couple of years ago, CDSCO had shown a green flag to Zydus Cadila's tetravalent inactivated influenza vaccine for seasonal flu. Medical Dialogues had earlier reported that Zydus had received approvals from the Drug Controller General of India (DCGI), CDSCO and Central Drug Laboratory (CDL) to market the tetravalent inactivated influenza vaccine Vaxiflu 4 for seasonal flu. For instance, Influenza is a major respiratory pathogen causing annual outbreaks and occasional pandemics.


    Also Read: Zydus Cadila to launch seasonal flu vaccine in India


    Presently, GSK's proposal for a waiver of the phase III trial regarding the Inactivated Influenza Vaccine has not been considered and the firm has been recommended to conduct the same.


    GSK is an Indian subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.


    Its product portfolio includes prescription medicines and vaccines. It's prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases.


    The company also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others.

    anti infectives cancer Cardiovascular disease CDSCO Central Drugs Standard Control Organization cervical cancer chickenpox Dermatology diabetes diphtheria Drug Controller General of India Flu vaccine GlaxoSmithKline GSK gynaecology hepatitis A hepatitis B Inactivated vaccines influenza invasive disease Medical Devices oncology pandemics pertussis Phase III phase III trial respiratory diseases respiratory pathogen rotavirus SEC Committee Split Virion tetanus vaccine vaccines Virion zydus Zydus Cadila 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X